Expertise in
27
conditions

Dr. Sharon A. Spencer

Radiation Oncology
UAB Women And Infants Center
1700 6th Ave S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
UAB Women And Infants Center
1700 6th Ave S, 
Birmingham, AL 

Overview

Sharon Spencer is a Radiation Oncologist practicing medicine in Birmingham, Alabama.

Dr. Spencer is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Oral Squamous Cell Carcinoma, Ewing Sarcoma, and Gastrostomy.

She is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 11 clinical trials. Dr. Spencer is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in AL

Hospital Affiliations

University Of Alabama Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UAB Women and Infants Center
1700 6th Ave S, Birmingham, AL 35233
Other Locations
University of Alabama Hospital
619 19th St S, Birmingham, AL 35233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
View 9 Less Clinical Trials

74 Total Publications

Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 27, 2026
Similar Doctors
Expertise in
22
conditions
Dr. John B. Fiveash
Radiation Oncology
Expertise in
22
conditions
Dr. John B. Fiveash
Radiation Oncology
Referral may be required

UAB O'Neal Comprehensive Cancer Center At Acton Road

2145 Bonner Way, 
Birmingham, AL 
 (6.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Fiveash is a Radiation Oncologist practicing medicine in Birmingham, Alabama. Dr. Fiveash is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Metastatic Brain Tumor, Astrocytoma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Fiveash is currently accepting new patients.

Expertise in
19
conditions
Dr. Christopher D. Willey
Radiation Oncology
Expertise in
19
conditions
Dr. Christopher D. Willey
Radiation Oncology
Referral may be required

UAB Women And Infants Center

1700 6th Ave S, 
Birmingham, AL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Willey is a Radiation Oncologist practicing medicine in Birmingham, Alabama. Dr. Willey is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Tissue Biopsy, and Gastrostomy. Dr. Willey is currently accepting new patients.

Expertise in
45
conditions
Dr. Michael C. Dobelbower
Radiation Oncology
Expertise in
45
conditions
Dr. Michael C. Dobelbower
Radiation Oncology
Referral may be required

UAB O'Neal Comprehensive Cancer Center At Acton Road

2145 Bonner Way, 
Birmingham, AL 
 (6.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Dobelbower is a Radiation Oncologist practicing medicine in Birmingham, Alabama. Dr. Dobelbower is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Meningioma, Lung Cancer, Pleuropulmonary Blastoma, and Gastrostomy. Dr. Dobelbower is currently accepting new patients.

Frequently Asked Questions about Dr. Sharon A. Spencer

How do I make an appointment with Dr. Sharon A. Spencer?

You can book an appointment with Dr. Sharon A. Spencer by calling their office at 205-934-5670. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sharon A. Spencer a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sharon A. Spencer is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sharon A. Spencer specialize in?

While Dr. Sharon A. Spencer is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Throat Cancer, and Oral Squamous Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Sharon A. Spencer participate in research or clinical trials?

Yes. Dr. Sharon A. Spencer has published 74 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Sharon A. Spencer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sharon A. Spencer accept my insurance?

Dr. Sharon A. Spencer accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 205-934-5670 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spencer's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile